Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 21 2020 - 4:39PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of
1934
For the month of December 2020
Commission File Number 001-38716
GAMIDA
CELL LTD.
(Translation of registrant’s name
into English)
Nahum Heftsadie Street
Givaat Shaul, Jerusalem 91340 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On December 17, 2020, we entered into
an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and Evercore Group L.L.C., as
representatives of the several underwriters named therein, pursuant to which we agreed to issue and sell, in an underwritten public
offering, an aggregate of 9,343,750 ordinary shares (the “Shares”), inclusive of the underwriters’ full exercise
of their 30-day option to purchase up to an additional 1,218,750 Shares, at a public offering price of $8.00 per share, for aggregate
gross proceeds of $74.75 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Under the terms of the Underwriting Agreement,
the Shares were offered pursuant to a registration statement on Form F-3 (File No. 333-234701), which was filed with the Securities
and Exchange Commission on November 14, 2019 and was declared effective on November 27, 2019. A copy of the Underwriting Agreement
is filed as Exhibit 1.1 to this report, and the foregoing description of the terms of the Underwriting Agreement does not purport
to be complete and is qualified in its entirety by reference to such exhibit. A copy of the opinion of Meitar | Law Offices relating
to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1. A copy of the press release
announcing the offering is furnished as Exhibit 99.1 to this Form 6-K. A copy of the press release announcing the closing and
the full exercise of the underwriters’ option to purchase additional shares is furnished as Exhibit 99.2 to this Form 6-K.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
|
|
GAMIDA CELL LTD.
|
|
|
|
December 21, 2020
|
By:
|
/s/ Shai Lankry
|
|
|
Shai Lankry
|
|
|
Chief Financial Officer
|
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024